SUPERNUS PHARMACEUTICALS, INC. Increase (Decrease) in Interest Payable, Net
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Increase (Decrease) in Interest Payable, Net of $101.00 thousand for the 9-month period ending 2012-09-30, per its 10-Q filed 2012-11-02.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInterestPayableNet · last filed 2012-11-02
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in interest payable, net for the quarter ending 2012-09-30 was -$20.00K.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in interest payable, net for the quarter ending 2012-06-30 was -$12.00K.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in interest payable, net for the quarter ending 2012-03-31 was $133.00K, a 3.62% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in interest payable, net for the quarter ending 2011-09-30 was $0.00.
| Period end | Increase (Decrease) in Interest Payable, Net 3 month | Increase (Decrease) in Interest Payable, Net 6 month | Increase (Decrease) in Interest Payable, Net 9 month |
|---|---|---|---|
| 2012-09-30 | -$20.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-02 | -$32.00K derived: sum of 2 quarters · filed 2012-11-02 | $101.00K 10-Q · filed 2012-11-02 |
| 2012-06-30 | -$12.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-13 | $121.00K 10-Q · filed 2012-08-13 | |
| 2012-03-31 | $133.00K 10-Q · filed 2012-06-08 | ||
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-02 | $0.00 derived: sum of 2 quarters · filed 2012-11-02 | $138.00K 10-Q · filed 2012-11-02 |
| 2011-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-13 | $138.00K 10-Q · filed 2012-08-13 | |
| 2011-03-31 | $138.00K 10-Q · filed 2012-06-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |